Moxifloxacin-induced torsades de pointes.
Torsade de pointes (TdP) is increasingly recognized as a complication of drug therapy. The most common cause of drug-induced QT prolongation is inhibition of the rapidly activating component of the delayed potassium current (I(Kr)). Moxifloxacin, a widely used fluoroquinolone, is a weak I(Kr) inhibitor and has been associated with QT prolongation. We report a case of marked QT prolongation (618 ms) and TdP associated with moxifloxacin use. Although it is difficult to predict which patients are at risk from TdP, careful assessment of the risk/benefit ratio is important before prescribing drugs known to cause QT prolongation.
Sherazi
Saadia
S
Unity Health System, Department of Medicine, University of Rochester Medical Center, Rochester, NY 14626, USA.
DiSalle
Michael
M
Daubert
James P
JP
Shah
Abrar H
AH
D000368:Aged; D000890:Anti-Infective Agents / Q000009:adverse effects*; D001372:Aza Compounds / Q000009:adverse effects*; D004562:Electrocardiography; D024841:Fluoroquinolones; D006801:Humans; D008297:Male; D000077266:Moxifloxacin; D011804:Quinolines / Q000009:adverse effects*; D016171:Torsades de Pointes / Q000139:chemically induced* / Q000175:diagnosis
D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000077266:Moxifloxacin